ACAD-12 Inhibitors

Chemical inhibitors of acyl-Coenzyme A dehydrogenase family, member 12 (ACAD12) operate through various mechanisms to reduce the availability of substrates required for the enzyme to function. Triacsin C, for instance, directly impairs the activity of long-chain acyl-CoA synthetase, thereby limiting the production of fatty acid substrates necessary for beta-oxidation, a process in which ACAD12 is involved. Similarly, Perhexiline and Etomoxir work by inhibiting carnitine O-palmitoyltransferase (CPT1), thereby preventing long-chain fatty acids from being transported into the mitochondria for oxidation, which consequently decreases the substrate pool for ACAD12. Moreover, Malonyl-CoA acts as a natural inhibitor of CPT1, further contributing to the reduction in substrate transport into the mitochondria and inhibiting ACAD12 by substrate depletion.

In addition to these inhibitors, Oxfenicine also targets CPT1, impeding the mitochondrial uptake of fatty acids and thereby reducing their availability for ACAD12-mediated metabolism. Ranolazine, on the other hand, partially blocks mitochondrial long-chain 3-ketoacyl-CoA thiolase, which is a downstream step in the beta-oxidation pathway. This leads to an accumulation of intermediates that can indirectly suppress ACAD12 activity. Mildronate diminishes the production of carnitine, a crucial molecule for fatty acid transport into mitochondria, thus indirectly limiting ACAD12's access to substrates. Benzafibrate, by activating peroxisome proliferator-activated receptors, alters fatty acid metabolism and may decrease substrate availability for ACAD12. AICAR, by activating AMP-activated protein kinase, leads to decreased malonyl-CoA levels and consequently affects CPT1 activity, impacting ACAD12 indirectly. GSK2194069 inhibits fatty acid synthase, thus reducing the synthesis of new fatty acids and indirectly influencing ACAD12 activity due to substrate scarcity. ST1326, by inhibiting acyl-CoA:diacylglycerol acyltransferase 1, diverts fatty acids away from storage and toward oxidation, which could decrease substrate availability for ACAD12. Lastly, CPI-613's activation of TCA cycle enzymes can increase the use of acetyl-CoA for energy production, potentially reducing the availability of fatty acyl-CoAs for beta-oxidation and thereby diminishing ACAD12 activity.